Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ALIM is in the long-term down -88% below S&P in 8 years.
Description: Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company?s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient?s eye to a placement site that uses the eye?s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dain
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.5||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||79.82%||Sales Growth - Q/Q||126.19%||P/E||-2.68|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-25.76%||ROE||-61.48%||ROI||-29.4%|
|Current Ratio||5.86||Quick Ratio||5.69||Long Term Debt/Equity||0.74||Debt Ratio||0.3|
|Gross Margin||88.7%||Operating Margin||-355.13%||Net Profit Margin||-242.72%||Dividend Payout Ratio|
|Cash From Financing Activities||-200 K||Cash From Investing Activities||-160 K||Cash From Operating Activities||-14.7 M||Gross Profit||3.65 M|
|Net Profit||-9.79 M||Operating Profit||-10.99 M||Total Assets||96.83 M||Total Current Assets||70.31 M|
|Total Current Liabilities||11.99 M||Total Debt||34.53 M||Total Liabilities||56.26 M||Total Revenue||3.94 M|
|High 52 week||1.3||Low 52 week||0.75||Last close||0.91||Last change||2.55%|
|RSI||34.87||Average true range||0.05||Beta||0.9||Volume||265.7 K|
|Simple moving average 20 days||-2.23%||Simple moving average 50 days||-9.84%||Simple moving average 200 days||-7.95%|
|Performance Week||-3.2%||Performance Month||-5.09%||Performance Quart||-7.16%||Performance Half||-18.03%|
|Performance Year||-23.54%||Performance Year-to-date||-1.12%||Volatility daily||3.57%||Volatility weekly||7.99%|
|Volatility monthly||16.37%||Volatility yearly||56.69%||Relative Volume||294.18%||Average Volume||107.21 K|
|New High||New Low|
2019-11-14 12:45:00 | Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split
2019-11-13 08:00:00 | Alimera Sciences Terminates Equity Purchase Agreement
2019-11-07 18:00:00 | Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio
2019-11-05 05:06:39 | One Thing To Remember About The Alimera Sciences, Inc. NASDAQ:ALIM Share Price
2019-10-02 08:00:00 | Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019
2019-09-03 08:00:00 | Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication
2019-08-06 07:24:36 | How Much Of Alimera Sciences, Inc. NASDAQ:ALIM Do Institutions Own?
2019-07-31 18:06:42 | Edited Transcript of ALIM earnings conference call or presentation 30-Jul-19 1:00pm GMT
2019-06-04 05:34:09 | Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?
2019-05-21 08:24:12 | Top Ranked Momentum Stocks to Buy for May 21st
2019-05-01 17:18:10 | Edited Transcript of ALIM earnings conference call or presentation 30-Apr-19 1:00pm GMT
2019-04-23 08:30:00 | Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIENR to be Presented at the Association for Research and Vision in Ophthalmology ARVO Annual Meeting
2019-03-21 08:00:00 | Alimera Sciences Announces Approval for ILUVIEN R in Kuwait
2019-03-06 08:00:00 | Alimera Sciences Announces the Reimbursement of ILUVIENR in France
2019-02-20 10:31:03 | Will Alimera Sciences ALIM Report Negative Q4 Earnings? What You Should Know
2019-02-19 15:26:22 | Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT
2019-02-19 07:00:00 | Alimera Sciences, Inc. to Host Earnings Call
2019-02-18 16:15:00 | Alimera Sciences Reports Record Fourth Quarter and 2018 Results
2019-02-05 07:30:00 | Alimera Sciences Announces Approval for ILUVIENR in Lebanon
2019-01-30 11:07:20 | Eye implant is helping treat vision loss in diabetics
2019-01-07 06:30:00 | Alimera Sciences Affirms Record 2018 Revenues
2018-12-21 11:36:47 | What Type Of Shareholder Owns Alimera Sciences, Inc.’s NASDAQ:ALIM?
2018-12-17 07:00:00 | Alimera Sciences Announces Pricing Approval For ILUVIENR in the U.A.E.
2018-11-29 07:15:00 | Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
2018-11-26 15:30:00 | Alimera Sciences Announces Canadian Regulatory Approval for ILUVIENR